Tecentriq and Avastin revenue trends

In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.7 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively. In 1Q17, 2Q17, and 3Q17, Tecentriq generated revenues of 115 million Swiss francs, 121 million Swiss francs, and 128 million Swiss francs, respectively.

What to Expect from Roche’s Tecentriq and Avastin in 2018

IMmotion 151 trial

In December 2018, Roche announced results from the phase three IMmotion 151 trial. In the IMmotion 151 trial, Tecentriq and Avastin combination therapy met the co-primary endpoint of progression-free survival compared to sunitinib.

Roche conducted the phase three IMmotion 151 trial to evaluate the safety and efficacy of Tecentriq and Avastin combination therapy compared to sunitinib for the treatment of individuals with locally advanced or metastatic renal cell carcinoma who have not previously received systemic therapy.

In the IMmotion 151 trial, Tecentriq and Avastin demonstrated a statistically significant and clinically meaningful decrease in the risk of disease worsening or death (progression-free survival) in individuals with advanced or metastatic renal cell carcinoma whose tumors expressed PD-L1 (programmed death-ligand 1) protein compared to sunitinib as a first-line treatment.

The results of the clinical trial will be discussed with health authorities including the European Medicines Agency and the US Food and Drug Administration (or FDA).

About Tecentriq and Avastin

Tecentriq is indicated for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-containing chemotherapy or showed disease progression during or after any platinum-containing chemotherapy. Tecentriq is also indicated for the treatment of individuals with metastatic non-small cell lung cancer who showed disease progression during or after platinum-containing chemotherapy. Avastin is indicated for metastatic colorectal cancer.

Tecentriq’s peers include Pfizer’s (PFE) Bavencio, Bristol-Myers Squibb’s (BMY) Opdivo, and Merck’s (MRK) Keytruda. The revenue growth of Roche’s Avastin and Tecentriq could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up about ~0.69% of VEU’s total portfolio holdings.

Latest articles

15 Jul

Will Amazon Prime Day 2019 Break 2018's Record?

WRITTEN BY Jitendra Parashar

This year, Amazon extended its Prime Day to 48 hours instead of the 36-hour sale in July 2018, making the 2019 event the longest Prime Day ever.

In a series of tweets on Monday, Trump today weighed in on China’s GDP growth, which came in at a 27-year low.

15 Jul

OrganiGram's Third-Quarter Earnings

WRITTEN BY Adam Jones

On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

Trump is reportedly planning to increase the content of US-made steel in federal projects, which would be a lifeline for US steel companies.

Huawei is preparing for “extensive layoffs” in the US, which could put the US-China trade deal on the rocks.

With Q2's Netflix earnings just around the corner, here's what you can expect from the online streaming giant and the broader streaming space.